Plus FDA approves CTI’s pacritinib, Aurinia shares sink, Lexicon submission delayed, priority review for neoadjuvant Opdivo and more

Five submissions under FDA priority review

Plus FDA panel rebuffs Reata’s bardoxolone and updates from Radius, OncoMyx, Neurocrine and Merck & Co. 

Briefing document suggests FDA could deal Reata a setback in Alport syndrome 

Deal, worth up to $250M, makes Blackstone largest shareholder of U.K. biotech

Plus: On deck at ODAC, GenEdit, Worg-Apitope, Reata, Tyvyt and more 

The U.S. will release 60 million doses of the COVID-19 vaccine from AstraZeneca plc (LSE:AZN; NASDAQ:AZN) and the University of Oxford to other countries as they become available, according to Andy

FDA’s conclusion about data Reata added to a potentially registrational package for its Friedreich’s ataxia program sliced about $420 million from the company’s market cap, and

Life sciences group seeking to own stakes in drugs, make growth-stage bets

Two renal diseases are on track for their first approvals after a pair of Phase III studies hit primary endpoints, suggesting renewed interest in the therapeutic area is paying off for patients and